Unlock instant, AI-driven research and patent intelligence for your innovation.

Compositions and methods for imaging

A technology for conjugating and binding fragments, applied in the field of compositions and methods for imaging, which can solve problems such as failure to reflect systemic immunological status, failure to reflect overall immune status, and failure to capture therapy

Pending Publication Date: 2021-04-09
TAYU HUAXIA BIOTECH MEDICAL GRP CO LTD
View PDF90 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although FFPE-pretreated primary tumor samples may be most readily available, these samples may not reflect the overall immune status currently present in a given patient, especially if interim treatment has been administered
Lack of PD-L1 expression in biopsy lesions may not reflect systemic immunological status and may not capture beneficial effects of therapy at other sites of disease that depend on PD-L1 signaling
In summary, there is an unmet need for accurate alternative PD-L1 detection agents and methods

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for imaging
  • Compositions and methods for imaging
  • Compositions and methods for imaging

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach 1

[0442] Embodiment 1. Antibody pharmaceuticals comprising an antibody portion, wherein the antibody portion is an antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (V H ) and the light chain variable region (V L ), where: a) V H Comprising: HC-CDR1 containing the amino acid sequence of SEQ ID NO:41, HC-CDR2 containing the amino acid sequence of SEQ ID NO:42, and HC-CDR3 containing the amino acid sequence of SEQ ID NO:43, or in HC-CDR Variants thereof containing up to a total of about 5 amino acid substitutions; and b) V L Comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:44, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:45, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:46, or in LC-CDR Variants thereof contain up to a total of about 5 amino acid substitutions.

Embodiment approach 2

[0443] Embodiment 2. The antibody agent of embodiment 1, wherein: a) V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:41, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:42, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO:43; and / or b) V L Comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:44, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:45, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:46.

Embodiment approach 3

[0444] Embodiment 3. The antibody agent of embodiment 1 or 2, wherein: a) V H comprising an amino acid sequence having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NO: 1, 5, 9, 11 and 13; and b) V L Comprising an amino acid sequence having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 3, 7, 15, 17 and 19.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
melting pointaaaaaaaaaa
Login to View More

Abstract

The present application provides methods, imaging agents and kits for determination of the distribution and expression levels of an immune checkpoint ligand (such as PD-L1 or a PD-L1 like ligand) in an individual having a disease or condition. Anti-PD-L1 antibody agents are also provided.

Description

[0001] Submit a sequence listing as an ASCII text file [0002] The content of the subsequent submission as an ASCII text file is hereby incorporated by reference in its entirety: Computer Readable Form of the Sequence Listing (CRF) (File Name: 792572000240SEQLIST.TXT, Date of Record: July 23, 2018, Size: 62KB). [0003] field of invention [0004] The present invention relates to antibodies, imaging agents and methods for imaging immune checkpoint ligands. [0005] Background of the invention [0006] The programmed death (PD) network involves at least five interacting molecules: PD-1 (programmed cell death 1), two PD-1 ligands (PD-L1 and PD-L2), and two Inhibitory receptors (PD-1 and CD80). Key functions of the PD pathway in regulating T-cell activity in surrounding tissues in the inflammatory response to infection and in limiting autoimmunity appear to be hijacked by tumor cells and the virus during chronic viral infection. PD-L1 is overexpressed in many freshly isolated ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P35/00A61P37/00A61K49/06C07K16/28C12N15/63C12N15/13
CPCA61P35/00A61P37/00A61K51/0495A61K51/0497A61K51/044C07K16/2827C07K2317/24C07K2317/33C07K2317/92C07K2317/94C07K2317/64C07K2317/565C07K2317/56C07K2317/622A61K51/0482A61K2039/505A61K2039/545C07K2317/52
Inventor 陈列平罗利群温振国刘千勇
Owner TAYU HUAXIA BIOTECH MEDICAL GRP CO LTD